Geode Capital Management
KNSA icon

Geode Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Geode Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.13M Sell
44,320
-1,463
-3% -$64.8K ﹤0.01% 3093
2025
Q4 		$1.89M Buy
45,783
+221
+0.5% +$8.87K ﹤0.01% 3191
2025
Q3 		$1.77M Sell
45,562
-5,380
-11% -$175K ﹤0.01% 3217
2025
Q2 		$1.41M Sell
50,942
-454,509
-90% -$11.6M ﹤0.01% 3233
2025
Q1 		$11.2M Buy
505,451
+12,821
+3% +$264K ﹤0.01% 2216
2024
Q4 		$9.74M Buy
492,630
+9,654
+2% +$220K ﹤0.01% 2398
2024
Q3 		$12.1M Sell
482,976
-365,918
-43% -$8.91M ﹤0.01% 2270
2024
Q2 		$15.8M Buy
848,894
+123,383
+17% +$2.31M ﹤0.01% 2058
2024
Q1 		$14.3M Buy
725,511
+25,898
+4% +$506K ﹤0.01% 2114
2023
Q4 		$12.3M Buy
699,613
+40,044
+6% +$658K ﹤0.01% 2222
2023
Q3 		$11.5M Buy
659,569
+46,917
+8% +$790K ﹤0.01% 2178
2023
Q2 		$8.63M Buy
612,652
+43,323
+8% +$580K ﹤0.01% 2375
2023
Q1 		$6.13M Buy
569,329
+24,992
+5% +$329K ﹤0.01% 2543
2022
Q4 		$8.15M Buy
544,337
+20,864
+4% +$304K ﹤0.01% 2391
2022
Q3 		$6.72M Sell
523,473
-7,996
-2% -$91.1K ﹤0.01% 2512
2022
Q2 		$5.15M Buy
531,469
+12,175
+2% +$114K ﹤0.01% 2685
2022
Q1 		$5.16M Sell
519,294
-13,923
-3% -$148K ﹤0.01% 2781
2021
Q4 		$6.28M Buy
533,217
+56,822
+12% +$698K ﹤0.01% 2763
2021
Q3 		$5.43M Buy
476,395
+17,536
+4% +$228K ﹤0.01% 2863
2021
Q2 		$6.39M Buy
458,859
+35,950
+9% +$546K ﹤0.01% 2754
2021
Q1 		$7.83M Buy
422,909
+44,427
+12% +$909K ﹤0.01% 2522
2020
Q4 		$6.69M Buy
378,482
+31,593
+9% +$555K ﹤0.01% 2423
2020
Q3 		$5.31M Buy
346,889
+111,903
+48% +$2.1M ﹤0.01% 2362
2020
Q2 		$5.99M Buy
234,986
+30,837
+15% +$644K ﹤0.01% 2228
2020
Q1 		$3.16M Buy
204,149
+13,631
+7% +$213K ﹤0.01% 2422
2019
Q4 		$2.11M Buy
190,518
+24,617
+15% +$214K ﹤0.01% 2972
2019
Q3 		$1.41M Buy
165,901
+3,792
+2% +$41.9K ﹤0.01% 3105
2019
Q2 		$2.19M Buy
162,109
+12,013
+8% +$186K ﹤0.01% 2896
2019
Q1 		$2.71M Buy
150,096
+53,345
+55% +$1.03M ﹤0.01% 2675
2018
Q4 		$2.72M Sell
96,751
-372
-0.4% -$7.76K ﹤0.01% 2587
2018
Q3 		$2.48M Buy
+97,123
New +$1.89M ﹤0.01% 2775

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Geode Capital Management's KNSA Position: Q1 2026 in Review

Geode Capital Management reduced its Kiniksa Pharmaceuticals (KNSA) stake by 3.2% in Q1 2026, selling an estimated $64.8K and leaving 44,320 shares worth $2.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3093.

Geode Capital Management first reported a position in KNSA in Q3 2018 and has held it in 31 quarters since. The position peaked at $15.8M in Q2 2024. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Geode Capital Management held 44,320 shares of Kiniksa Pharmaceuticals worth $2.13M as of Q1 2026.
  • Geode Capital Management sold 1,463 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $64.8K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3093 holding.
  • Geode Capital Management first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • Geode Capital Management's Kiniksa Pharmaceuticals position peaked at $15.8M in Q2 2024.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.